US Companies Benefit Most from European Research Council

A recent study has reinforced the concept of the "European Paradox," revealing a significant gap in Europe’s ability to convert high-quality scientific research into marketable innovations. The findings, published in the journal *Research Policy*, align with internal research conducted by the European Research Council (ERC), which has long noted this trend. The study indicates that while Europe excels in producing excellent basic science, it struggles to leverage this research effectively for commercial gain. In contrast, U.S. organizations, particularly companies, are shown to be more successful in capitalizing on ERC-funded research, leading to greater economic benefits. This disparity raises concerns about Europe's competitiveness in the global innovation landscape. The ERC's ongoing efforts to address this issue highlight the need for improved mechanisms to facilitate the translation of scientific discoveries into practical applications. The findings suggest that without significant changes, Europe risks falling further behind in the race for innovation and economic growth. As the conversation around research funding continues, stakeholders are urged to consider strategies that enhance collaboration between researchers and industry. The study serves as a call to action for policymakers and funding bodies to rethink their approaches to ensure that Europe's scientific advancements translate into tangible benefits for society.